ACP-105 (NEW)

[sjgpharma]

What Is ACP-105?

ACP-105 is another non-steroidal Selective Androgen Receptor Modulator (SARM). It is as potent as Testosterone in in vitro assays without interaction at other hormone receptors. In addition, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostate in preclinical models.

How Suppressive Is ACP-105?

ACP-105 is a partial agonist; meanwhile LGD-4033 is a full agonist (using this comparison as LGD-4033 has a lot of supporting data to compare to).

Full agonists induce greater levels of suppression, but are more potent (based on the information presented).

With ACP-105 in particular, being a partial agonist it would result in less suppression, although it will also likely be weaker than LGD-4033 on a mg:mg comparison.

Raising the dose could make it formidable to heavy hitters like LGD-4033, but referring back to the anabolic:androgenic rating of ACP-105 (3.19:1), we can assume that the higher the dose, the greater the chance of suppression and androgenic side effects.

This may still be minimal though, even at higher dosages, as ACP-105 appears to have a much less significant effect on prostate size than Testosterone and DHT.

Dosage

The studies done on ACP-105 suggest that the human equivalent for the study using 1 mg/kg per day for a man weighing about 175 pounds would be about 11 mg per day.

Obviously equating this to some efficacious dosage where there would be minimal/no side effects for human use is impossible to do without some sort of experimentation being done, and as of now there are no clinical trials done on humans.

The consensus seems to suggest that a reasonable starting dosage is around 11-12mg per day for human research trials.